Skip to main
TNYA

Tenaya Therapeutic (TNYA) Stock Forecast & Price Target

Tenaya Therapeutic (TNYA) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Tenaya Therapeutics Inc. demonstrates a promising outlook due to observed consistent improvements in left ventricular mass and dimensions, alongside increased chances of success for its product candidates, TN-201 and TN-401, which are now projected at 30% and 15%, respectively. The company has shown clinically meaningful advancements in cardiac biomarkers and patient classifications, suggesting a pathway for accelerated approval that aligns with successful peer programs. Additionally, the encouraging safety profile observed thus far, as evidenced by the tapering off of immunosuppression regimen without adverse effects, further strengthens the investment case for the company's innovative therapeutic approaches.

Bears say

Tenaya Therapeutics's stock faces a negative outlook primarily due to the potential delays in transitioning its preclinical assets to clinical trials, which could adversely affect market sentiment and lead to downward revisions in financial estimates. Additionally, the emergence of safety signals, particularly related to immune reactions during later-stage trials, poses significant risks that could further depress valuations. Compounding these challenges is the concern regarding insufficient manufacturing capacity, which could materially constrain projected growth and financial forecasts.

Tenaya Therapeutic (TNYA) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tenaya Therapeutic and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tenaya Therapeutic (TNYA) Forecast

Analysts have given Tenaya Therapeutic (TNYA) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Tenaya Therapeutic (TNYA) has a Strong Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tenaya Therapeutic (TNYA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.